Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 11,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Priapism, Sickle Cell Disease, Hypogonadism
Interventions: Transdermal Androgel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Gaucher Disease
Interventions: AT2101; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Exocrine Pancreatic Insuficiency
Interventions: Fecal Fat; Diagnostic Test
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more

Conditions: Familial Adenomatous Polyposis
Interventions: Black raspberry (BRB) Slurry, Black Raspberry (BRB) Suppositories, Black Raspberry (BRB) Placebo Slurry; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cystic Fibrosis
Interventions: Hyperpolarized Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 12 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Friedreich's Ataxia
Interventions: Interferon γ-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 26 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Conditions: Adrenomyeloneuropathy, Adrenoleukodystrophy
Interventions: Lorenzo's oil; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Salt Lake City, Utah

Conditions: Phenylketonuria
Interventions: saproterin dihydrochloride, Diet treatment; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancers
Interventions: Laparoscopic surgery; Procedure
Lead sponsor: Erin Rowell; Other
Eligibility: Up to 11 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Skin Laxity
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Fragile X Syndrome
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 68 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Atomoxetine; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 4 Years to 11 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glycogen Storage Disease Type II
Interventions: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding; Other
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Video recording, Medication Administration Log, Education; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mucopolysaccharidosis II, MPS II
Interventions: SB-913; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Cardiovascular Disease
Interventions: Model 7600 Regional Oximeter System; Device
Lead sponsor: Nonin Medical, Inc; Industry
Eligibility: Up to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Stanford, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: MP-376 (Levofloxacin solution for Inhalation), placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Tourette Syndrome, Tic Disorders
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Lebanon, New Hampshire • Charlottesville, Virginia

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Dexamethasone Early, Dexamethasone Late; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 13 Days to 15 Days
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions: Genistein, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Kidney Transplant
Interventions: Berinert, Placebo for Berinert; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Neonatal Abstinence Syndrome
Interventions: donor human milk; Dietary Supplement
Lead sponsor: Neolac Inc dba Medolac Laboratories; Industry
Eligibility: 38 Weeks to 42 Weeks
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

Androgen Regulation of Priapism in Sickle Cell Disease

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

The Effectiveness of Kuvan in Amish PKU Patients

Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal)

Feasibility Study: Lifting and Tightening of the Elbows

Trial of Sertraline to Treat Children With Fragile X Syndrome

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease

Use of Mobile Technology for Intensive Training in Medication Management

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Study of Non-Invasive Regional Oxygen Saturations in Pediatric Patients Undergoing Cardiac Catheterization

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

Dexamethasone Therapy in VLBW Infants at Risk of CLD

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

Donor Human Milk in Neonatal Abstinence Syndrome